Background
==========

Wilms tumor, or nephroblastoma, is a malignant embryonal tumor of the kidney that most commonly occurs in the neonatal and pediatric population and has typical histological characteristics with undifferentiated blastema tissue, epithelial and mesenchymal elements \[[@b1-medscimonit-26-e920725]--[@b3-medscimonit-26-e920725]\]. Wilms tumor represents approximately 90% of pediatric renal tumors and 5% of all the pediatric tumors, and 98% of patients are less than 10 years old. In the UK, 8.1 out of 1,000,000 children were diagnosed with Wilms tumor as new cases annually. For example, in the UK, 90 new cases of Wilms tumor occurred annually, while in the US, the number was higher, with 650 children diagnosed annually \[[@b4-medscimonit-26-e920725],[@b5-medscimonit-26-e920725]\]. In China, Xinjiang is an area with a high incidence of Wilms tumor in children, and most children present with late-stage malignancy. Several research centers in China have reported that the 5-year disease-free survival (DFS) rates of stage II and stage III Wilms tumor were 78% and 78.2%, respectively \[[@b6-medscimonit-26-e920725],[@b7-medscimonit-26-e920725]\]. The overall survival (OS) rate of Wilms tumor is relatively greater, at \>90% when compared with other tumors, but there is still a need for further studies \[[@b6-medscimonit-26-e920725],[@b7-medscimonit-26-e920725]\]. Poor prognosis in approximately 25% of patients is associated with high-risk tumors, bilateral lesions, and tumor recurrence. Current treatments for Wilms tumor can have side effects, and up to 25% of survivors suffer from severe chronical health problems at 25 years following diagnosis \[[@b8-medscimonit-26-e920725],[@b9-medscimonit-26-e920725]\]. Therefore, there is a need to continue to study the molecular mechanisms of Wilms tumor and to find molecular targets for future drug therapy.

Several recent studies have investigated the molecular pathogenesis of Wilms tumor to identify relevant genes, to discover new treatment targets and more effective therapy. For example, Wang et al. showed that EGF, CDK1, ENDRA, NGFR, OIP5, NUF2, and CDCA8 might have a role in the development of high-risk Wilms tumor by using weighted gene co-expression network analysis (WGCNA) to identify the hub genes involved in tumor progression \[[@b10-medscimonit-26-e920725]\]. Also, Wilms tumor was shown to be associated with the overexpression of miR-483-5p, mutation of TRIM28, and polymorphisms of miR-423 rs6505162 C\>A \[[@b11-medscimonit-26-e920725]--[@b13-medscimonit-26-e920725]\]. However, despite these findings, molecular studies on the treatment for Wilms tumor are still limited.

Gene therapy for malignancy has gained increasing importance in clinical research \[[@b14-medscimonit-26-e920725]\]. Drug discovery and development is expensive and takes many years. However, a more economical strategy is to study existing drugs that potentially target cancer-related genes \[[@b15-medscimonit-26-e920725]\]. The Connectivity Map (CMap) database, developed by the Broad Institute in the USA, is an accessible and sophisticated resource that is available to help to establish the relationships between disease characteristics and differentially expressed genes (DEGs) in human disease, and following treatment \[[@b16-medscimonit-26-e920725]\]. Molecular docking is an approach to binding the predicted drugs to particularly selected proteins, which allows investigators to analyze the docking of the ligand to the target, and to understand the chemical and structural basis of the target specificity \[[@b14-medscimonit-26-e920725],[@b17-medscimonit-26-e920725]--[@b19-medscimonit-26-e920725]\]. Molecular docking can detect the molecular initiating events (MIEs) that occur in the pathways that are associated with treatment side effects \[[@b14-medscimonit-26-e920725],[@b17-medscimonit-26-e920725]--[@b19-medscimonit-26-e920725]\] An increasing number of studies have been conducted based on CMap and molecular docking to identify more effective drugs for the treatment of malignancy, including breast carcinoma, cervical carcinoma, prostate carcinoma, and carcinoma of the lung \[[@b20-medscimonit-26-e920725]--[@b22-medscimonit-26-e920725]\]. However, there have been few recent studies that mapped the potential drug targets in Wilms tumor.

Therefore, this study aimed to use bioinformatics data, the RNA-sequencing data resources Genotype-Tissue Expression (GTEx) and the TARGET targeted RNA-sequencing (RNA-Seq) database, connectivity mapping using CMap, molecular docking, and ligand-protein binding to identify potential targets for drug therapy in Wilms tumor.

Material and Methods
====================

Acquisition of differentially expressed genes (DEGs) of Wilms tumor from different databases and enrichment analysis
--------------------------------------------------------------------------------------------------------------------

The TARGET targeted RNA-sequencing (RNA-Seq) database was used that contained detailed data about from childhood tumors, including RNA, whole-genome sequencing (WGS), whole-exome sequencing (WES), copy number variants (CNVs), gene methylation, and clinical data. This study used the open controlled-access data in the TARGET targeted RNA-sequencing (RNA-Seq) database that was acquired from Data Matrix (*<http://ocg.cancer.gov/programs/target/data-matrix>*). Non-tumor controls were obtained from Genotype-Tissue Expression (GTEx) (*<https://www.gtexportal.org/home/index.html>*). The standards were \|logFC\| \>1 and adjPVal \<0.01.

The DEGs were identified using the voom method in the limma package. Also, this study included the WEB-based Gene SeT AnaLysis Toolkit (WebGestalt) (*<http://www.webgestalt.org/>*) and the Metascape gene annotation and analysis resource (*<http://metascape.org/>*) to perform Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis of 980 DEGs with significant adjPVal for false discovery rate (FDR)-adjusted p-values, to investigate the biological process and molecular mechanism.

The prediction of candidate drugs based on DEGs using the Connectivity Map (CMap) database
------------------------------------------------------------------------------------------

DEGs were selected with a significant adjPVal value, and converted to probe number HG133A assigned by Affymetrix (*<http://www.affymetrix.com/>*). The CMap database (Broad Institute, Cambridge, MA, USA) (*<https://portals.broadinstitute.org/cmap/>*) contained 6,100 cases and 1,309 small molecules, which were used to investigate the interactions between small molecule drugs, DEGs and Wilms tumor. Assisted by the annotations, it was possible to choose the candidate drugs according to the gene expression profile of each case. Because CMap could process up to 1,000 pieces of probe information, the probe numbers of the 980 DEGs with significant adjPVal were grouped into the upregulation and down-regulation categories. The data were then input into CMap, and the drugs with a score \<−0.9 were deemed as potential drug candidates.

The prediction of target genes and the enrichment analysis
----------------------------------------------------------

When the drugs with a score \<−0.9 were input into PubChem (*<https://pubchem.ncbi.nlm.nih.gov/>*), and their corresponding simplified molecular-input line-entry system (SMILES) line notation structures were acquired. The SMILE structures were input into the search tool for interactions of chemicals (STITCH) database (*<http://stitch.embl.de/>*), and the results were compared with 980 identified DEGs. The thermal maps were drawn with the drug target genes to illustrate their expression levels in both cancer and non-cancer cohorts.

The Benjamini--Hochberg (BH) procedure was used for the KEGG pathway analysis by the ORA method of WebGestalt and the pathways with an FDR \<0.05 were compared with the DEGs-enriched pathways. Further analysis was performed if the DEGs and drug target genes overlapped, and the sequencing data were highly expressed in the Wilms tumor.

The molecular docking using systemsDock
---------------------------------------

Molecular docking assesses the behavior of the small molecule binding site of the target protein, and this study used the systemsDock website for drug prediction and analysis (*<https://omictools.com/systemsdock-tool>*). The overlapping DEGs and drug target genes were selected as the drug target genes for Wilms tumor. The upregulated genes in Wilms tumor were docked with the relevant drugs on systemsDock.

Clinical significance and prognosis analysis
--------------------------------------------

Gene databases that were searched included the Gene Expression Omnibus (GEO), ArrayExpress, and Oncomine to identify the importance of overlapping genes and to obtain gene profiles associated with Wilms tumor. The criteria for screening included expression profiles from histological samples associated with the Wilms tumor and available clinical data. Box plots examined the clinical significance of the overlapping genes. The receiver operating characteristic (ROC) curves, and the standardized mean difference (SMD) were analyzed using GraphPad Prism version 8.0 (GraphPad Software, La Jolla, CA, USA) and STATA 12.0 (Stata Corporation, College Station, TX, USA). Of the 177 cases identified from TARGET and GTEx, 126 cases had corresponding prognostic information. A modification used in this study was the analysis of the prognostic information through survival package in R, including Kaplan-Meier curves and hazard ratios (HRs). The final expression value of each gene was obtained by the average, if the gene corresponded to different probes. According to the annotated information of each expression profile, all data not marked as standardized were processed using the log~2~ ratio. A P-value \<0.05 was considered to be statistically significant.

Results
=======

The identification of differentially expressed genes (DEGs) and the enrichment analysis
---------------------------------------------------------------------------------------

This study included 177 tumor and non-tumor gene sequencing data of Wilms tumors identified from the Genotype-Tissue Expression (GTEx) and TARGET databases. There were 980 DEGs chosen with significant adjPVal for false discovery rate (FDR)-adjusted p-values, which included 648 upregulated genes and 342 downregulated genes. The Gene Ontology (GO) enrichment analysis included biological process, cellular component, and molecular function. The top 10 enriched pathways are listed in [Table 1](#t1-medscimonit-26-e920725){ref-type="table"}. Also, the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of DEGs and other relevant analysis are also shown in [Figure 1](#f1-medscimonit-26-e920725){ref-type="fig"}.

The prediction of drug candidates for the DEGs
----------------------------------------------

The Connectivity Map (CMap) database assisted in the comparison of the DEGs and identified a possible 21 therapeutic targets (score \<−0.9) that were considered to be potential therapeutic targets for Wilms tumor ([Table 2](#t2-medscimonit-26-e920725){ref-type="table"}).

The prediction of target genes for the drug candidates
------------------------------------------------------

The target genes predicted by the search tool for interactions of chemicals (STITCH) database as potential drug candidates were obtained. The overlapping 75 target genes were selected for further analysis ([Figure 2A, 2B](#f2-medscimonit-26-e920725){ref-type="fig"}). Analysis of the overlap with the DEGs identified seven commonly overlapping genes that included CRAPB2, CDK2, SIRT1, CA12, MAP4K4, KCNJ1, and ADNP. The pathway analysis showed that the 75 target genes and 980 DEGs showed no significance in the KEGG pathways ([Figure 2C](#f2-medscimonit-26-e920725){ref-type="fig"}).

The docking of drug candidates to the overlapping genes
-------------------------------------------------------

Of the seven overlapping genes, except CA12, six genes were highly expressed in Wilms tumors. The six upregulated genes in Wilms tumor were then docked to four drugs, retinoic acid, gliclazide, alsterpaullone, and trans-resveratrol by targeting these genes. The docking scores of ADNP and KCNJ1 could not be calculated as they did not have the corresponding numbers in the Protein Data Bank (PDB) database. The docking scores of the other four genes to the four drugs showed relatively high scores when retinoic acid and alsterpaullone were docked to the four genes ([Figure 3](#f3-medscimonit-26-e920725){ref-type="fig"}). The results of docking are shown in three-dimension in [Figure 4](#f4-medscimonit-26-e920725){ref-type="fig"}, and in two-dimensions in [Figure 5](#f5-medscimonit-26-e920725){ref-type="fig"}.

Clinical significance and prognostic significance of the four overlapping genes, CRAPB2, CDK2, SIRT1, and MAP4K4
----------------------------------------------------------------------------------------------------------------

The high docking scores between the two drugs and the four overlapping genes, CRAPB2, CDK2, SIRT1, and MAP4K4, showed the importance of the analysis. Four data series were screened that may be used for standardized mean difference (SMD) analysis, including GSE11024, GSE4530, GSE73209, and GSE2712. The results of the SMD are shown in [Table 3](#t3-medscimonit-26-e920725){ref-type="table"}. The clinical significance and the overlapping genes are shown in [Figures 6](#f6-medscimonit-26-e920725){ref-type="fig"} and [7](#f7-medscimonit-26-e920725){ref-type="fig"}. The Kaplan-Meier curves and the hazard ratio (HR) were used to investigate the mRNA expression of the four genes, as shown in [Figure 8](#f8-medscimonit-26-e920725){ref-type="fig"}.

Discussion
==========

The current treatment for children with Wilms tumor includes chemotherapy, which is given before or after surgery. Despite the increased cure rate for Wilms tumor following multimodal therapy, the recurrence rate remained relatively high (15%) for patients with low-grade Wilms tumor, and the five-year survival rate remains poor \[[@b23-medscimonit-26-e920725]--[@b26-medscimonit-26-e920725]\]. Therefore, an increasing number of studies have included the search for drugs to target the relevant genes in Wilms tumor, and have included salidroside and curcumin \[[@b27-medscimonit-26-e920725],[@b28-medscimonit-26-e920725]\]. However, recent studies were based on *in vitro* or *in vivo* experiments on a specific drug, to identify or demonstrate the drug effects on Wilms tumor. However, the present study demonstrated the use of the Connectivity Map (CMap) database and molecular docking to conduct bioinformatics analysis of the sequencing data using several databases and showed that retinoic acid and alsterpaullone had potential treatment effects by affecting the differentially expressed genes (DEGs) of Wilms tumor, and identified the four genes, CRABP2, CDK2, MAP4K4, and SIRT1. Also, this study included enrichment analysis of DEGs, multi-factorial survival analysis, and weighted gene co-expression network analysis (WGCNA) analysis, which made this study the study more comprehensive.

Retinoic acid is the bioactive metabolite of Vitamin A, which is a compound that potentially prevents or treats malignancy and which participates in multiple biological processes \[[@b29-medscimonit-26-e920725],[@b30-medscimonit-26-e920725]\]. Retinoic acid can suppress the growth of cancer cells *in vitro* and induces cell death in breast cancer, neuroblastoma, gastric carcinoma, prostate cancer, pancreatic cancer, and acute promyelocytic leukemia cells \[[@b31-medscimonit-26-e920725]--[@b33-medscimonit-26-e920725]\]. In 2005, molecular studies showed that the trans-retinoic acid gene (ATRA) had the potential for the treatment for Wilms tumor. In advanced-stage tumors treated with ATRA, upregulation of several genes was found, including RARRES1, RARRES3, CRABP2, IGFBP3, RARB, RARG, and TRIM22, and the transforming growth factor-β pathway was activated to induce the inhibition of cell growth \[[@b34-medscimonit-26-e920725]\]. The findings from the present study were consistent with those from previous studies and supported that CRABP2 functioned as a DEG in Wilms tumor and was a target gene of retinoic acid. Also, CDK2, MAP4K4, and SIRT1 might serve as targets for retinoic acid, which may be a future direction for studies on the molecular mechanisms of retinoic acid in the treatment of Wilms tumor.

Also, the findings from this study supported that alsterpaullone might have a role in the treatment of Wilms tumor. Alsterpaullone is an inhibitory small molecule that affects the cell cycle to suppress the cytoactivity of tumor cells and causes apoptosis of some tumor cells. Alsterpaullone may also act as a cyclin-dependent kinase (CDK) modulator that can compete with ATP for the binding site of CDK \[[@b35-medscimonit-26-e920725],[@b36-medscimonit-26-e920725]\]. Lahusen et al. first showed that alsterpaullone could induce apoptosis and accelerate the loss of clonogenicity in the Jurkat cell line \[[@b37-medscimonit-26-e920725]\]. Also, previous studies showed that alsterpaullone was a potential treatment for hepatoblastoma, cervical carcinoma, and ovarian carcinoma \[[@b35-medscimonit-26-e920725],[@b36-medscimonit-26-e920725],[@b38-medscimonit-26-e920725]\]. Despite these findings, there have been no previous studies on the role of alsterpaullone in Wilms tumor. This study analyzed the sequencing data by using bioinformatics and showed that from all the upregulated genes in Wilms tumor, the docking CRABP2, CDK2, MAP4K4, and SIRT1 genes to alsterpaullone resulted in higher scores. These findings indicated that alsterpaullone could interfere with the biological processes of Wilms tumor, possibly by targeting these four genes. Therefore, alsterpaullone might have the potential as a new drug for the treatment of Wilms tumor.

The DEGs for Wilms tumor were enriched in three main pathways that included DNA replication, mismatch repair, and the cell cycle. Alsterpaullone had an inhibitory role by influencing the cell cycle. Based on the docking results, alsterpaullone might accelerate apoptosis by interfering with the cell cycle in Wilms tumor. However, further studies are needed to verify these molecular mechanisms. The standardized mean difference (SMD) of three overlapping genes, CDK2, MAP4K4, and CRABP2, were significant in this study. However, the heterogeneity of the SMD analysis was large, and no statistically significant prognostic results were obtained, possibly due to a comparatively small study sample. Therefore, further studies are required to validate these findings.

Conclusions
===========

This study aimed to use bioinformatics data, RNA-sequencing, connectivity mapping, molecular docking, and ligand-protein binding to identify potential targets for drug therapy in Wilms tumor. RNA-sequencing, connectivity mapping, and molecular docking to investigate ligand-protein binding identified retinoic acid and alsterpaullone as potential drug candidates for the treatment of Wilms tumor.
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![The bioinformatics analysis of differentially expressed genes (DEGs) in Wilms tumor. (**A**) Volcano plot. (**B**) Thermal map. (**C**) The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. FDR -- false discovery rate.](medscimonit-26-e920725-g001){#f1-medscimonit-26-e920725}

![The bioinformatics analysis of target genes for the drug candidates. (**A**) Venn diagram. (**B**) Thermal map. (**C**) The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. FDR, false discovery rate.](medscimonit-26-e920725-g002){#f2-medscimonit-26-e920725}

![The docking results shown as bar charts. (**A**) Retinoic acid. (**B**) Alsterpaullone.](medscimonit-26-e920725-g003){#f3-medscimonit-26-e920725}

![The molecular interactions between drugs and genes are shown in three-dimension. (**A**) Retinoic acid and CDK2. (**B**) retinoic acid and MAP4K4. (**C**) retinoic acid and CRABP2. (**D**) Retinoic acid and SIRT1. (**E**) Alsterpaullone and CDK2. (**F**) Alsterpaullone and MAP4K4. (**G**) Alsterpaullone and CRABP2. (**H**) Alsterpaullone and SIRT1.](medscimonit-26-e920725-g004){#f4-medscimonit-26-e920725}

![The molecular interactions between drugs and genes are shown in two-dimensions. (**A**) Retinoic acid and CDK2. (**B**) Retinoic acid and MAP4K4. (**C**) Retinoic acid and CRABP2. (**D**) Retinoic acid and SIRT1. (**E**) Alsterpaullone and CDK2. (**F**) Alsterpaullone and MAP4K4. (**G**) Alsterpaullone and CRABP2. (**H**) Alsterpaullone and SIRT1.](medscimonit-26-e920725-g005){#f5-medscimonit-26-e920725}

![The differential expression and the receiver operating characteristic (ROC) curves of the overlapping genes for molecular docking. (**A**) Differential expression of CDK2. (**B**) ROC of CDK2. (**C**) Differential expression of MAP4K4. (**D**) ROC of MAP4K4. (**E**) Differential expression of CRABP2. (**F**) ROC of CRABP2. (**G**) Differential expression of SIRT1. (**H**) ROC of SIRT1.](medscimonit-26-e920725-g006){#f6-medscimonit-26-e920725}

![The forest plots of standardized mean difference for the overlapping genes. (**A**) CDK2 (P=0.008). (**B**) MAP4K4 (P=0.007). (**C**) CRABP2 (P\<0.001). (**D**) SIRT1 (P=0.077).](medscimonit-26-e920725-g007){#f7-medscimonit-26-e920725}

![The prognostic significance of overlapping genes shown by the Kaplan-Meier curves for the four genes, CDK2, MAP4K4, CRABP2, and SIRT1. (**A**) Kaplan-Meier curves of CDK2. (**B**) Kaplan-Meier curves of MAP4K4. (**C**) Kaplan-Meier curves of CRABP2. (**D**) Kaplan-Meier curves of SIRT1. (**E**) Hazard ratio (HR) of the four genes.](medscimonit-26-e920725-g008){#f8-medscimonit-26-e920725}

###### 

Gene Ontology enrichment analysis of differentially expressed genes in Wilms tumor.

  Gene Set                 Description                                                     Size   Expect   Ratio    P Value    FDR
  ------------------------ --------------------------------------------------------------- ------ -------- -------- ---------- ----------
  **Biological process**                                                                                                       
  GO: 0007049              Cell cycle                                                      1739   81.91    2.7591   0          0
  GO: 0022402              Cell cycle process                                              1274   60.008   3.0663   0          0
  GO: 0051726              Regulation of cell cycle                                        1106   52.095   2.6106   0          0
  GO: 0006259              DNA metabolic process                                           970    45.689   3.0204   0          0
  GO: 0000278              Mitotic cell cycle                                              927    43.663   3.9163   0          0
  GO: 0006974              Cellular response to DNA damage stimulus                        806    37.964   2.7131   0          0
  GO: 0007346              Regulation of mitotic cell cycle                                578    27.225   3.5262   0          0
  GO: 0045786              Negative regulation of cell cycle                               559    26.33    2.9624   0          0
  GO: 0006281              DNA repair                                                      511    24.069   3.2822   0          0
  GO: 0006260              DNA replication                                                 268    12.623   5.2284   0          0
  **Cellular component**                                                                                                       
  GO: 0044430              Cytoskeletal part                                               1621   60.433   2.1511   0          0
  GO: 0015630              Microtubule cytoskeleton                                        1165   43.433   2.901    0          0
  GO: 0005694              Chromosome                                                      1014   37.803   4.8938   0          0
  GO: 0044427              Chromosomal part                                                886    33.031   5.298    0          0
  GO: 0005815              Microtubule organizing center                                   722    26.917   2.9349   0          0
  GO: 0000228              Nuclear chromosome                                              573    21.362   5.1961   0          0
  GO: 0044454              Nuclear chromosome part                                         535    19.945   5.1641   0          0
  GO: 0000785              Chromatin                                                       509    18.976   4.6374   0          0
  GO: 0000790              Nuclear chromatin                                               341    12.713   4.4836   0          0
  GO: 0000793              Condensed chromosome                                            223    8.3137   6.7359   0          0
  **Molecular Function**                                                                                                       
  GO: 0003690              Double-stranded DNA binding                                     915    41.274   2.5682   0          0
  GO: 0003682              Chromatin binding                                               520    23.456   3.1974   0          0
  GO: 1990837              Sequence-specific double-stranded DNA binding                   823    37.124   2.3974   9.10E-15   5.70E-12
  GO: 0044212              Transcription regulatory region DNA binding                     896    40.417   2.2515   1.87E-13   7.99E-11
  GO: 0001067              Regulatory region nucleic acid binding                          898    40.507   2.2465   2.13E-13   7.99E-11
  GO: 0003697              Single-stranded DNA binding                                     107    4.8266   5.1796   7.64E-12   2.39E-09
  GO: 0042393              Histone binding                                                 192    8.6608   3.8103   2.98E-11   8.00E-09
  GO: 0043565              Sequence-specific DNA binding                                   1097   49.484   1.9804   4.15E-11   9.73E-09
  GO: 0001012              RNA polymerase II regulatory region DNA binding                 735    33.155   2.232    6.25E-11   1.28E-08
  GO: 0000976              Transcription regulatory region sequence-specific DNA binding   781    35.23    2.1857   6.80E-11   1.28E-08

GO -- Gene Ontology; FDR -- false discovery rate.

###### 

Ten potential drugs for Wilms tumor acquired from the Connectivity Map database.

  Rank   Batch   CMap name             Dose    Cell   Score    Up       Down    Instance_id
  ------ ------- --------------------- ------- ------ -------- -------- ------- -------------
  1      713     Menadione             23 μM   PC3    −1.000   −0.261   0.277   4662
  2      702     Promazine             12 μM   PC3    −0.998   −0.306   0.230   4308
  3      1066    Alsterpaullone        10 μM   MCF7   −0.981   −0.253   0.275   7051
  4      502     Resveratrol           10 μM   MCF7   −0.981   −0.323   0.205   958
  5      514     Tyrphostin AG-825     25 μM   MCF7   −0.97    −0.278   0.244   1114
  6      701     Cloperastine          11 μM   PC3    −0.954   −0.272   0.241   4271
  7      688     Fluvoxamine           9 μM    PC3    −0.944   −0.277   0.231   3995
  8      701     Fenoprofen            7 μM    PC3    −0.937   −0.272   0.232   4274
  9      764     1,4-chrysenequinone   15 μM   PC3    −0.927   −0.259   0.24    7139
  10     505     Ionomycin             2 μM    MCF7   −0.916   −0.305   0.188   882
  11     502     Quinostatin           10 μM   MCF7   −0.914   −0.297   0.195   973
  12     714     Flupentixol           8 μM    PC3    −0.913   −0.296   0.195   6708
  13     753     Zoxazolamine          24 μM   PC3    −0.908   −0.270   0.219   6290
  14     665     Iopanoic acid         7 μM    HL60   −0.908   −0.26    0.229   2965
  15     704     Sulpiride             12 μM   PC3    −0.906   −0.244   0.244   4566
  16     772     8-azaguanine          26 μM   MCF7   −0.906   −0.283   0.204   7444
  17     762     Nortriptyline         13 μM   PC3    −0.905   −0.294   0.192   7300
  18     719     Gliclazide            12 μM   PC3    −0.903   −0.264   0.222   5089
  19     1075    GW-8510               10 μM   PC3    −0.901   −0.271   0.214   7085
  20     694     Benperidol            10 μM   MCF7   −0.901   −0.277   0.208   4781
  21     746     Tretinoin             13 μM   MCF7   −0.901   −0.285   0.200   6243

CMap -- the connectivity map.

###### 

The standardized mean difference of four overlapping genes.

  Gene     SMD     95% CI            P-value   I^2^     P (I^2^)
  -------- ------- ----------------- --------- -------- ----------
  CDK2     1.429   (0.376--2.482)    0.008     80.90%   0.001
  MAP4K4   2.656   (0.717--4.595)    0.007     87.70%   \<0.001
  CRABP2   1.931   (0.910--2.952)    \<0.001   77.50%   0.004
  SIRT1    1.537   (−0.165--3.239)   0.077     87.70%   \<0.001

SMD -- standardized mean difference; CI -- confidence interval.
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